BRAF mutation is seen in
**Core Concept**
BRAF mutation is a genetic alteration that involves the BRAF gene, which encodes a protein called B-Raf that plays a crucial role in regulating cell growth and division. This mutation leads to an abnormal activation of the mitogen-activated protein kinase (MAPK) pathway, resulting in unchecked cell proliferation and cancer.
**Why the Correct Answer is Right**
The BRAF V600E mutation is a specific type of mutation that occurs in the BRAF gene, where glutamic acid (E) is substituted for valine (V) at position 600. This mutation results in the constitutive activation of the B-Raf protein, leading to the activation of the MAPK pathway and the development of various cancers, including melanoma. The BRAF V600E mutation is a well-known oncogenic driver and is often targeted by specific therapies, such as BRAF inhibitors.
**Why Each Wrong Option is Incorrect**
**Option A:** Mutations in the KRAS gene are more commonly associated with colorectal cancer and other malignancies. While KRAS mutations do activate the MAPK pathway, they are distinct from the BRAF V600E mutation.
**Option B:** The EGFR gene encodes a protein that is involved in cell growth and division, but EGFR mutations are more commonly associated with non-small cell lung cancer and other malignancies. EGFR mutations are not directly related to the BRAF V600E mutation.
**Option C:** The PIK3CA gene encodes a protein that is involved in the PI3K/AKT signaling pathway, which is distinct from the MAPK pathway activated by the BRAF V600E mutation. PIK3CA mutations are more commonly associated with breast and other cancers.
**Option D:** The TP53 gene encodes a protein that is involved in cell cycle regulation and DNA repair, but TP53 mutations are more commonly associated with various cancers, including Li-Fraumeni syndrome. TP53 mutations are not directly related to the BRAF V600E mutation.
**Clinical Pearl / High-Yield Fact**
The BRAF V600E mutation is a well-known oncogenic driver that is targeted by specific therapies, such as BRAF inhibitors. These therapies can be effective in treating melanoma and other cancers with this mutation, but resistance to therapy can develop over time.
**Correct Answer:** C. Melanoma